Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo

  • Authors:
    • Dan Li
    • Yingli Jin
    • Ying Sun
    • Jing Lei
    • Chaoying Liu
  • View Affiliations

  • Published online on: June 2, 2014     https://doi.org/10.3892/ijo.2014.2479
  • Pages: 813-821
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Toll-like receptor 4 (TLR4)-mediated signaling has been implicated in tumor cell invasion, survival and metastasis in several types of cancers. However, the expression of TLR4 in patients with non-small cell lung cancer (NSCLC) and its biological function in the development and progression of NSCLC have not been elucidated to date. Here, we sought to characterize the expression of TLR4 in patients with NSCLC and to investigate the biological roles of TLR4 in lung metastasis, cell invasion and survival. In this study, we found that TLR4 expression was elevated in most patients with NSCLC, and its expression levels correlated with key pathological characteristics, including tumor differentiation, stage and metastasis. Our data also showed that downregulation of TLR4 expression using an RNA silencing approach in A549 tumor cells significantly suppressed cell proliferation, cell migration and cell invasion, and induced tumor apoptosis in vitro, and suppressed tumor growth in vivo. In addition, we also found that downregulation of TLR4 expression significantly decreased cell TNF-α and IL-6 levels. Furthermore, we found that knockdown of TLR4 was able to significantly suppress constitutive phosphorylation of Akt and PI3K, which may contribute to the inhibition of tumor growth. These data suggest that TLR4 plays an important role in tumorigenic properties of human NSCLC, and that RNA interference-directed targeting of TLR4 could be used as a potential anticancer therapeutic target in NSCLC.

References

1 

Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar

2 

Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Schiller JH: Small cell lung cancer: defining a role for emerging platinum drugs. Oncology. 63:105–114. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int. 2013:9647432013.PubMed/NCBI

5 

Medzhitov R, Preston-Hurlburt P and Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:394–397. 1997. View Article : Google Scholar

6 

Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar

7 

Medzhitov R and Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science. 296:298–300. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Elson G, Dunn-Siegrist I, Daubeuf B and Pugin J: Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood. 109:1574–1583. 2007. View Article : Google Scholar : PubMed/NCBI

9 

De Bouteiller O, Merck E, Hasan UA, et al: Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem. 280:38133–38145. 2005.PubMed/NCBI

10 

Goto Y, Arigami T, Kitago M, et al: Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 7:3642–3653. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Kelly MG, Alvero AB, Chen R, et al: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Fukata M, Chen A, Vamadevan AS, et al: Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 133:1869–1881. 2007. View Article : Google Scholar : PubMed/NCBI

13 

O’Neill LA, Bryant CE and Doyle SL: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 61:177–197. 2009.PubMed/NCBI

14 

Yu L and Chen S: Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ and Perez-Perez GI: Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 −251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer. 7:702007.PubMed/NCBI

16 

Wang JP, Zhang Y, Wei X, et al: Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS. 118:261–270. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Yang H, Zhou H, Feng P, et al: Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 29:922010. View Article : Google Scholar : PubMed/NCBI

18 

He W, Liu Q, Wang L, Chen W, Li N and Cao X: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Hiratsuka S, Watanabe A, Sakurai Y, et al: The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 10:1349–1355. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Zhang YB, He FL, Fang M, et al: Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep. 36:1475–1481. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.

22 

Campo E, Merino MJ, Liotta L, Neumann R and Stetler-Stevenson W: Distribution of 72KD type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol. 23:1395–1401. 1992. View Article : Google Scholar : PubMed/NCBI

23 

Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI

24 

Zhang D, Chen ZG, Liu SH, et al: Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Acta Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Mendez M, Custodio A and Provencio M: New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis. 3:30–56. 2011.PubMed/NCBI

26 

Yao H and Rahman I: Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol. 9:375–383. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Bauer AK, Dixon D, DeGraff LM, et al: Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst. 97:1778–1781. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Bauer AK, Fostel J, Degraff LM, et al: Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis. Mol Cancer. 8:1072009. View Article : Google Scholar : PubMed/NCBI

29 

Szczepanski MJ, Czystowska M, Szajnik M, et al: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 69:3105–3113. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Huang B, Zhao J, Li H, et al: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI

31 

Hua D, Liu MY, Cheng ZD, et al: Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 46:2876–2884. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Ahmed A, Wang JH and Redmond HP: Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol. 20(Suppl 3): S389–S396. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Kusmartsev S and Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother. 51:293–298. 2002. View Article : Google Scholar : PubMed/NCBI

35 

Gatti G, Quintar AA, Andreani V, et al: Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate. 69:1387–1397. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Starska K, Forma E, Brys M, et al: The expression of TLR pathway molecules in peripheral blood mononuclear cells and their relationship with tumor invasion and cytokine secretion in laryngeal carcinoma. Adv Med Sci. 57:124–135. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Hartmann E, Wollenberg B, Rothenfusser S, et al: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63:6478–6487. 2003.PubMed/NCBI

38 

Oka N, Tanimoto S, Taue R, et al: Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci. 97:1093–1098. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Kai K, D’Costa S, Sills RC and Kim Y: Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett. 278:49–55. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2014
Volume 45 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, D., Jin, Y., Sun, Y., Lei, J., & Liu, C. (2014). Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo. International Journal of Oncology, 45, 813-821. https://doi.org/10.3892/ijo.2014.2479
MLA
Li, D., Jin, Y., Sun, Y., Lei, J., Liu, C."Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo". International Journal of Oncology 45.2 (2014): 813-821.
Chicago
Li, D., Jin, Y., Sun, Y., Lei, J., Liu, C."Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo". International Journal of Oncology 45, no. 2 (2014): 813-821. https://doi.org/10.3892/ijo.2014.2479